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Tumor-infiltrating plasmacytoid dendritic cells (pDCs) promote an immuno-
suppressive milieu that drives tumor growth in melanoma. This phenomenon
typically results from the lack of appropriate pDC activation signals in the
tumor microenvironment, but it is also actively controlled by tumor cells,
which have evolved strategies to inhibit type I IFN production by pDCs.
In this issue, Camisaschi et al. identify a new mechanism in which tumors
avoid type I IFN production by triggering LAG-3-dependent activation of pDCs.
Combination therapies that restore pDC functionality and trigger innate activation
to produce type I IFN should be envisaged to induce effective antitumor
immunity.
Journal of Investigative Dermatology (2014) 134, 1797–1800. doi:10.1038/jid.2014.155
Melanoma is considered a prototypical
immunogenic tumor expressing several
melanoma-associated antigens that can
be recognized by T cells. Despite the
expression of these antigens, melanoma
patients usually fail to mount sponta-
neous immune responses that are
capable of rejecting tumors. One of
the reasons for this is lack of an ade-
quate innate immune response required
to initiate the immune apparatus.
Another reason is the dominant immu-
nosuppressive microenvironment orche-
strated by the tumor itself through
production of immunosuppressive cyto-
kines (vascular endothelial growth fac-
tor, IL-10, and transforming growth
factor-b) and the recruitment of T regu-
latory cells or myeloid-derived suppres-
sor cells. Recently, plasmacytoid
dendritic cells (pDCs) were found
to contribute to the establishment of
an immunosuppressive milieu in many
cancers. In contrast, pDCs and their
activation to produce type I IFNs were
found to induce protective antitumor
immunity. Understanding the delicate
balance between these apparently
divergent functions of pDCs may pro-
vide new therapeutic avenues for treat-
ing melanomas and possibly other
cancers.
pDC and type I IFN-driven immunity
pDCs are known for their role in anti-
viral immunity, owing to their ability to
produce massive amounts of type I IFNs
in response to viral nucleic acid upon
recognition by Toll-like receptors (TLRs)
7 and 9 (Gilliet et al., 2008). Through
the production of type I IFNs, pDCs
initiate antiviral immunity by inducing
maturation of mDCs, activation of
natural killer cells, antibody production
by plasma cells, proliferation and cross-
priming of Th1 cells, and inhibition of T
regulatory cell function (Theofilopoulos
et al., 2005). pDC-derived type I IFNs
are also involved in the pathogenesis of
autoimmune disorders, as their aberrant
recognition of self-nucleic acids triggers
chronic type I IFN production and
sustained immune activation (Gilliet
et al., 2008).
pDCs in melanoma
The presence of pDCs has been
described in the tumor microenviron-
ment of many cancers including ovar-
ian, breast, head and neck, and thyroid
cancers, and in multiple myeloma, and
it has been linked to tumor progres-
sion and poor patient survival. pDCs
have also been detected in both
primary melanoma and in melanoma
metastases, whereas they are not
present in normal skin or melanocytic
nevi (Vermi et al., 2003; Gerlini et al.,
2007). In melanoma, pDCs are found
mainly in clusters around blood vessels
and in close contact with tumor cells,
where they are recruited by SDF1 and
CCL20 produced by tumors or peri-
tumoral cells (Charles et al., 2010).
These pDCs normally do not produce
type I IFN, and their presence is associ-
ated with the growth of melanoma
(Vermi et al., 2003; Gerlini et al., 2007).
Mechanisms of pDC-driven
immunosuppression
In recent years, there has been increas-
ing effort devoted to understanding how
pDCs drive immunosuppression in
melanoma and other types of cancer.
Although several mechanisms were
identified, they all share the lack of an
efficient type I IFN production by pDCs
as a common feature.
Lack of pDC activation. Tumor pDCs
are often present in a nonactivated state,
because of the lack of TLR7 and TLR9
signals in the tumor microenvironment.
These nonactivated pDCs express high
levels of the ICOS ligand, along with low
levels of CD80 and CD86 (Ito et al.,
2007), a unique constellation of costimu-
latory molecules that selectively trigger the
expansion of a subset of ICOSþ FoxP3þ
T regulatory cells (Gilliet and Liu, 2002;
Ito et al., 2008). Within tumors, pDCs
were found in close proximity to ICOSþ
FOXP3þ regulatory T cells, and their
number correlates directly with that
of this regulatory T-cell subset (Conrad
et al., 2012), suggesting that tumor pDCs
promote immunosuppression by activating
and expanding ICOSþ FOXP3þ T regu-
latory cells through ICOS costimulation.
Independent studies have indeed demon-
strated that both pDCs and ICOSþ T
regulatory cells constitute strong predic-
tors of disease progression and poor
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clinical outcome in patients affected by
ovarian, breast, and thyroid cancer
(Conrad et al., 2012; Faget et al., 2012).
High numbers of ICOSþ T regulatory
cells have also been identified in human
melanoma (Martin-Orozco et al., 2010),
although a link to pDC infiltration has
not been established. Another mecha-
nism for T regulatory cell expansion by
pDCs on PD-L1-PD-1 costimulation has
been described in a model of murine
melanoma (Sharma et al., 2007).
Tumor-mediated suppression of IFN
production by pDCs. Tumor cells pro-
duce immunosuppressive cytokines PGE2,
IL-10, and transforming growth factor-b,
which directly suppress type I IFN produc-
tion by inhibiting TLR and IRF7 expression
in pDCs (Bekeredjian-Ding et al., 2009).
Furthermore, melanoma cells express
Wnt5a, which inhibits TLR-mediated
pDC activation and type I IFN produc-
tion. Type I IFN production is also inhi-
bited by ILT7, a cell-surface receptor
specifically expressed by pDCs. ILT7
interacts with the transmembrane protein
BST2 induced in cells upon type I IFN
exposure and constitutively expressed by
many cancer cells such as melanoma,
lung cancer, renal cell carcinoma, and
breast cancer. The interaction between
BST2 and ILT7 leads to inhibition of
TLR-induced type I IFN induction, where-
as upregulation of CD80 and CD86
costimulatory molecule expression is un-
affected. Under physiological conditions,
this may be an important negative feed-
back mechanism for preventing prolonged
IFN production after viral infection and
a sustained inflammatory response. In con-
trast, constitutive expression of BST2 by
cancer cells may inhibit TLR-mediated IFN
production by pDCs and promote tumor
immunosuppression.
Alternate maturation of pDCs by tumor
cells. In this issue, Camisaschi et al.
(2014) have identified the role of a
subset of pDCs expressing the lympho-
cyte activation gene-3 (LAG-3), a CD4-
related costimulatory receptor that binds
major histocompatibility complex class II
molecules in cancer immunosuppression.
LAG-3þ pDCs were found to infiltrate the
tumor microenvironment of melanoma
and to interact with HLA-DRþ mela-
noma cells in vivo. In vitro, the authors
show that HLA-DRþ melanoma cells
stimulate LAG-3þ pDCs to mature and
produce IL-6 without inducing type I IFNs.
Accordingly, LAG-3-expressing pDCs
displayed a partially activated phenotype
and produced IL-6 in vivo. pDC-derived
IL-6 induced CCL2 production by mono-
cytes, a key chemokine in the recruitment
of myeloid-derived suppressor cells into
the tumor site. Thus, the recruitment of
LAG-3þ pDCs into the tumors and their
activation in the absence of type I IFN
production may drive myeloid-derived
suppressor cell-mediated immunosup-
pression. An alternate activation pathway
induced in pDCs by tumor cells has been
observed in multiple myeloma (Chauhan
et al., 2009). Myeloma cells were found
to secrete low levels of IL-3, an inducer
of pDC activation and maturation. IL-3-
activated pDCs do not produce type I IFNs
but mature rapidly into DCs that drive the
generation of CD4þ and CD8þ T regu-
latory cells producing IL-10 (Gilliet and
Liu, 2002; Ito et al., 2007). Thus, multiple
myeloma cells drive an alternate pathway
of pDC activation leading to T regulatory
cell–mediated immunosuppression.
Therapeutic activation of tumor pDCs to
produce type I IFN
Spontaneously regressing melanomas
are characterized by the presence of
activated pDCs that produce type I
IFN, suggesting a role of these cytokines
in triggering antitumor immune
responses (Wenzel et al., 2005).
Furthermore, treatment of skin tumors
with TLR7 and TLR9 agonists appears to
activate pDCs to produce type I IFN and
to induce local tumor regressions.
Topical application of the TLR7 agonist
imiquimod is currently used for the
treatment of superficial basal cell
carcinomas, actinic keratosis, and
lentigo maligna and was shown to
induce type I IFN production by tumor
pDCs as a central event in the local
antitumor effect (Urosevic et al., 2005).
Some regression of primary human
melanoma and superficial in-transit
melanoma metastasis has also been
reported, although topical imiquimod
is usually ineffective for this indication
as monotherapy. The local tumor
regression induced by topical
imiquimod is dependent on both pDCs
and type I IFN, as it was largely abro-
gated in pDC-depleted or IFNAR /
mice in a melanoma tumor model
(Drobits et al., 2012). The antitumor
effect was local, entirely independent
of T cells, but mediated by cytotoxic
molecules TRAIL and granzyme
induced in pDCs by autocrine type I
IFN signaling (Stary et al., 2007).
Another study, however, using a
melanoma mouse model, led to the
elicitation of systemic T cell–mediated
antitumor immunity through intra-
tumoral injection of the TLR9 agonist
CpG-ODN. This study demonstrated
that the induction of systemic T cell–
mediated antitumor immunity was dri-
ven in part by activation of intratumor
pDCs (Lou et al., 2011). The potential of
activated pDCs to stimulate systemic T
cell–mediated immunity at the tumor
site was confirmed by an elegant study
showing that intratumoral injection of
blood-derived CpG-activated pDCs
(therefore not conditioned by the tumor)
would elicit systemic T cell–mediated
tumor regression (injected versus non-
injected tumors) by promoting acti-
vation of natural killer cells and
cDCs that prime tumor-specific T cells
(Liu et al., 2008). Although type I IFN
had a central role in this process, a
contribution of other factors such as
Clinical Implications
 Tumor-infiltrating plasmacytoid dendritic cells (pDCs) promote an
immunosuppressive milieu that drives tumor growth.
 Tumor cells actively sustain the immunosuppressive functions of pDCs by
inhibiting their type I IFN production.
 Therapeutic activation of tumor pDCs using Toll-like receptor-7 (TLR7) and
TLR9 agonists can induce type I IFN production and antitumor immunity.
 Combined strategies to restore pDC functionality and stimulate TLR-
mediated activation of pDCs may be effective in increasing systemic
antitumor immunity.
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OX40L expressed by activated pDCs
was also demonstrated (Liu et al., 2008).
Therapeutic perspectives: functional
restoration of pDC function plus innate
activation
pDCs traffic into the tumor micro-
environment of melanoma and interact
with tumor cells so that the capacity
to produce type I IFNs is apparently
blocked. However, when properly acti-
vated by TLR7 and TLR9 ligands, pDCs
might provide type I IFNs to induce the
activation of the surrounding immune
cells and promote its own cytolytic
activity. Because tumor pDCs have a
reduced capacity to produce type I IFNs
upon stimulation with TLR agonists, one
strategy to ameliorate the antitumor
response is to restore full functionality
of pDCs before activation by
counteracting the tumor-derived inhibi-
tory function of pDCs. This may allow
the induction of systemic T cell–
mediated immunity with efficacy, not
only on treated tumors but also at
distant sites. Vicari et al. (2002)
showed that only the combination of
intratumoral CpG plus an anti-IL-10
antibody induced systemic T cell–
mediated immunity capable of rejecting
the tumors. As anti-LAG-3 is already in
clinical trials for cancer (Woo et al.,
2012), the use of this inhibi-
tory mAb, in combination with stimuli
of innate pDC activation (CpG or
imiquimod), could be advantageous in
inducing a more potent immune
response against the tumor. It appears
obvious that before stepping on the
accelerator, one needs to release the
brakes (Figure 1).
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Figure 1. pDCs in melanoma: turning bad into good. Melanoma drives pDC-mediated immunosuppression via three distinct mechanisms: (i) lack of activation,
(ii) active suppression of type I IFN production, and (iii) alternate activation bypassing type I IFN production. Because of the lack of activation signals, tumor pDCs
may retain an immature phenotype with high expression of ICOS ligand that costimulates T regulatory cells. Tumor cells also express BST2, and produce
transforming growth factor-b and IL-10, which actively inhibit type I IFN induction in pDCs. Finally, melanoma cells can trigger LAG3-dependent alternate
activation of pDC, leading to the production of IL-6 but not type I IFNs. pDC-derived IL-6 induces CCL2 production by monocytes, which initiates recruitment
of myeloid-derived suppressor cells into the tumor microenvironment. Therapeutically, the presence of pDCs at the tumor site could be exploited to drive
antitumor responses via their activation to produce type I IFNs using synthetic TLR7 and TLR9 agonists. Type I IFNs have the potential to unleash antitumor
immunity by activating conventional DCs, T cells, and NK cells while inhibiting regulatory T cells. Furthermore, type I IFNs can induce cytotoxic activities
of pDCs by inducing the expression of granzyme B and TRAIL, leading to local antitumor responses. The combined use of TLR agonists and neutralizing
antibodies that fully restore the ability of pDCs to produce type I IFNs (anti-LAG-3, anti-IL-10, or anti-ILT7) should be considered for the generation of more
effective antitumor responses. LAG-3, lymphocyte activation gene-3; mDC, myeloid dendritic cell; MDSC, myeloid-derived suppressor cell; MEL, melanoma;
Mono, monocyte; NK, natural killer cell; pDC, plasmacytoid dendritic cell; TLR, Toll-like receptor; T reg, T regulatory cell.
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Endoplasmic Reticulum Calcium,
Stress, and Cell-to-Cell Adhesion
Theodora Mauro1
Darier’s disease (DD) is caused by mutations in the endoplasmic reticulum (ER)
Ca2þ ATPase ATP2A2 (protein SERCA2). Current treatment modalities are
ineffective for many patients. This report shows that impaired SERCA2 function,
both in DD keratinocytes and in normal keratinocytes treated with the SERCA2-
inhibitor thapsigargin, depletes ER Ca2þ stores, leading to constitutive ER stress
and increased sensitivity to ER stressors. ER stress, in turn, leads to abnormal
cell-to-cell adhesion via impaired redistribution of desmoplakin, desmoglein 3,
desmocollin 3, and E-cadherin to the plasma membrane. This report illustrates
how ER Ca2þ depletion and the resulting ER stress are central to the pathogenesis
of the disease. Additionally, the authors introduce a possible new therapeutic
agent, miglustat.
Journal of Investigative Dermatology (2014) 134, 1800–1801. doi:10.1038/jid.2014.97
Darier’s disease
Darier’s disease (DD), caused by muta-
tions in the ER Ca2þ ATPase ATP2A2
(Sakuntabhai et al., 1999), is an un-
common (1:30,000) blistering skin
disease. Patients with DD suffer from
impaired cell-to-cell adhesion, defective
keratinocyte differentiation, and non-
physiological keratinocyte apoptosis.
Histologically, DD manifests with sup-
rabasal clefting in the epidermis,
acantholysis, rounded dyskeratotic kera-
tinocytes (‘‘corps ronds’’), hyperke-
ratosis and parakeratotic keratinocytes
in the stratum corneum (‘‘grains’’).
Current treatments, such as retinoids,
do not ameliorate the underlying defect
in ER Ca2þ sequestration, and are
ineffective for many patients.
This report, by Savignac et al. (2014,
this issue), advances our understanding
of DD in several important ways. First,
it illustrates how ER stress impairs the
formation of both adherens junctions
and desmosomes, contributing to DD
pathogenesis. Second, it expands our
understanding of how ER Ca2þ signal-
ing may control not only keratinocyte
growth and differentiation but also kera-
tinocyte cell-to-cell adhesion. Lastly, it
introduces a possible new therapeutic
agent, miglustat.
Defects in cell-to-cell adhesion in Darier’s
disease
Defects in desmoplakin redistribution
have been associated with the impaired
cell-to-cell adhesion seen in DD
(Dhitavat et al., 2003; Hobbs et al.,
2011). Defective desmoplakin redistri-
bution after SERCA2 Ca2þ depletion is
mediated by protein kinase C alpha
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